As measles outbreaks continue to escalate across the United States and globally, NanoViricides, Inc. (NYSE American: NNVC) is advancing its lead antiviral candidate, NV-387, toward a Phase II clinical trial for the treatment of measles. The company announced that it is developing a clinical trial protocol and intends to submit it to the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. This move comes as NV-387 has demonstrated strong in vivo efficacy against lethal measles infection in a humanized animal model, and has already received both Orphan Drug Designation and Rare Pediatric Disease Drug Designation from the FDA for measles treatment. The Rare Pediatric Disease designation could make NanoViricides eligible for a Priority Review Voucher upon approval of a qualifying marketing application, provided all requirements are met.
The urgency of this development is underscored by the recent surge in measles cases, which the Centers for Disease Control and Prevention (CDC) has linked to undervaccination. Measles is a highly contagious viral disease that can lead to severe complications, especially in children, including pneumonia, encephalitis, and death. Currently, there is no specific antiviral treatment for measles; standard care is supportive. NV-387, if proven effective, could fill a critical gap in measles management.
NanoViricides' platform is based on host-mimetic nanomedicine technology, which uses specially designed nanomaterials that mimic host cell receptors to attract and neutralize viruses. NV-387 is a broad-spectrum antiviral candidate that the company is developing for multiple respiratory viral infections, including RSV, COVID-19, influenza, and measles, as well as for poxvirus infections. The drug candidate has already shown promise in preclinical studies, and the company is now focused on advancing it into human trials.
The company's pipeline also includes NV-HHV-1 for shingles, and it is developing candidates for other viral diseases such as herpes, hepatitis, and influenza. However, the immediate focus is on NV-387, which the company believes has the potential to be a significant therapeutic option for measles and other viral threats.
The path to approval for any pharmaceutical product is lengthy and requires substantial capital. NanoViricides acknowledges that there can be no assurance that its candidates will demonstrate sufficient safety and efficacy in clinical trials. Nevertheless, the company's progress with NV-387 represents a step forward in addressing a re-emerging public health concern. The potential for a Priority Review Voucher, if NV-387 is approved, provides an additional incentive for the company to expedite development.
For more information on NanoViricides and its programs, visit the company's newsroom at https://ibn.fm/NNVC.
